Cell Biochemistry and Biophysics

, Volume 68, Issue 1, pp 201–206 | Cite as

Safety and Effectiveness of Nitroprusside in Preventing No-Reflow During Percutaneous Coronary Intervention: A Systematic Review

Translational Biomedical Research

Abstract

The objective of this study was to evaluate the clinical efficacy and safety of nitroprusside injection for preventing the slow-flow/no-reflow phenomenon after percutaneous coronary intervention (PCI). We searched the Cochrane Central Register of Controlled Trials (Issue 2, 2011), PubMed, EMbase, and Google Scholar for data. Two reviewers independently evaluated the quality of the included studies and extracted the data. A meta-analysis was performed using RevMan 5.0 software. Four randomized controlled trials (RCTs) involving 319 patients were included. The results of the meta-analyses showed that intracoronary nitroprusside is beneficial in preventing no-reflow/slow-flow, in reducing corrected TIMI frame count, and in improving left ventricular ejection fraction. It also likely reduces adverse reactions in patients after PCI and rehospitalization due to cardiovascular events. However, we must caution that in this review, there is a moderate possibility of bias with regard to patient selection, performance, and publication because of the small number of included studies. A larger sample size and high-quality RCTs are needed for a more reassuring analysis.

Keywords

No-reflow Percutaneous coronary intervention Nitroprusside Randomized controlled trial Systematic review 

References

  1. 1.
    Keeley, E. C., Boura, J. A., & Grines, C. L. (2003). Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet, 361, 13–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Kloner, R. A., Ganote, C. E., & Jennings, R. B. (1974). The no-reflow phenomenon after temporary coronary occlusion in the dog. Journal of Clinical Investigation, 54, 1496–1508.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Kelly, R. V., Cohen, M. G., & Stouffer, G. A. (2005). Incidence and management of “no-reflow” following percutaneous coronary interventions. American Journal of the Medical Sciences, 329, 78–85.PubMedCrossRefGoogle Scholar
  4. 4.
    Akdemir, R., Karakurt, O., Kilic, H., et al. (2010). Effect of reperfusion therapy on index of myocardial performance in acute myocardial infarction: Thrombolytics versus primary angioplasty. Heart and Vessels, 25, 87–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Bates, J. N., Baker, M. T., Guerra, R, Jr, & Harrison, D. G. (1991). Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochemical Pharmacology, 42(Suppl), S157–S165.PubMedCrossRefGoogle Scholar
  6. 6.
    Pan, W., Wang, L. F., Yu, J. H., et al. (2009). Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction. Chinese Medical Journal, 122, 2718–2723.PubMedGoogle Scholar
  7. 7.
    Hendler, A., Aronovich, A., Kaluski, E., et al. (2006). Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow. Journal of Invasive Cardiology, 18, 32–36.PubMedGoogle Scholar
  8. 8.
    Amit, G., Cafri, C., Yaroslavtsev, S., et al. (2006). Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. American Heart Journal, 152, 887.e9–887.e14.CrossRefGoogle Scholar
  9. 9.
    Sakamoto, H., Shimamoto, S., Kawase, Y., Ueda, H., Murakami, T., & Tamura, T. (2010). Effect of nitroprusside on reducing infarct size after primary percutaneous coronary intervention for acute myocardial infarction. Journal of the American College of Cardiology, 55, A104.E968.Google Scholar
  10. 10.
    Valero, S. J., Moreno, R., Reyes, R. M., et al. (2008). Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions. Cardiovascular and Hematological Agents in Medicinal Chemistry, 6, 125–129.PubMedCrossRefGoogle Scholar
  11. 11.
    Gibson, C. M., & Schomig, A. (2004). Coronary and myocardial angiography: Angiographic assessment of both epicardial and myocardial perfusion. Circulation, 109, 3096–3105.PubMedCrossRefGoogle Scholar
  12. 12.
    Tesic, M. B., Stankovic, G., Vukcevic, V., & Ostojic, M. C. (2010). The use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction. Herz, 35, 114–118.PubMedCrossRefGoogle Scholar
  13. 13.
    Airoldi, F., Briguori, C., Cianflone, D., et al. (2007). Frequency of slow coronary flow following successful stent implantation and effect of nitroprusside. American Journal of Cardiology, 99, 916–920.PubMedCrossRefGoogle Scholar
  14. 14.
    Pasceri, V., Pristipino, C., Pelliccia, F., et al. (2005). Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. American Journal of Cardiology, 95, 1358–1361.PubMedCrossRefGoogle Scholar
  15. 15.
    Kiernan, T. J., Ruggiero, N. J, I. I., Bernal, J. M., et al. (2009). The no-reflow phenomenon in the coronary circulation. Cardiovascular and Hematological Agents in Medicinal Chemistry, 7, 181–192.PubMedCrossRefGoogle Scholar
  16. 16.
    Kitakaze, M., Asakura, M., Kim, J., et al. (2007). Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet, 370, 1483–1493.PubMedCrossRefGoogle Scholar
  17. 17.
    Marzilli, M., Orsini, E., Marraccini, P., & Testa, R. (2000). Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation, 101, 2154–2159.PubMedCrossRefGoogle Scholar
  18. 18.
    Ross, A. M., Gibbons, R. J., Stone, G. W., Kloner, R. A., & Alexander, R. W. (2005). A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). Journal of the American College of Cardiology, 45, 1775–1780.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Qiang Su
    • 1
  • Lang Li
    • 1
  • Kyaw Aung Naing
    • 1
  • Yuhan Sun
    • 1
  1. 1.Department of CardiologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina

Personalised recommendations